Provided By GlobeNewswire
Last update: Aug 12, 2024
Enrollment commenced in the ACESOT-1051 Phase 1 trial evaluating APR-1051 – no myelosuppression observed in the first of eight planned cohorts at sub-therapeutic dose
NASDAQ:APRE (7/29/2025, 8:00:00 PM)
1.76
-0.12 (-6.47%)
Find more stocks in the Stock Screener